Morgan Stanley assumed coverage on shares of Immunocore (NASDAQ:IMCR – Get Rating) in a research note released on Friday morning, MarketBeat.com reports. The firm issued an overweight rating and a $77.00 target price on the stock.
A number of other equities analysts have also recently issued reports on IMCR. Cowen began coverage on Immunocore in a report on Monday, August 8th. They set an outperform rating on the stock. BTIG Research began coverage on Immunocore in a report on Tuesday, August 2nd. They set a buy rating and a $85.00 price target on the stock. LADENBURG THALM/SH SH began coverage on Immunocore in a report on Thursday. They set a buy rating and a $82.00 price target on the stock. Cowen began coverage on Immunocore in a report on Monday, August 8th. They issued an outperform rating and a $70.00 target price on the stock. Finally, HC Wainwright reiterated a buy rating and issued a $80.00 target price on shares of Immunocore in a report on Tuesday, July 5th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of Buy and an average target price of $75.00.
Immunocore Price Performance
Immunocore stock opened at $44.75 on Friday. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of -15.93 and a beta of -0.04. Immunocore has a 52-week low of $18.43 and a 52-week high of $61.32. The stock’s 50 day moving average price is $48.69 and its two-hundred day moving average price is $36.76. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.97 and a current ratio of 3.98.
Hedge Funds Weigh In On Immunocore
Immunocore Company Profile
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.
- Get a free copy of the StockNews.com research report on Immunocore (IMCR)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.